• ORM2 Regulates Pancreatic Fibrosis via ZG16-Dependent Autoph

  2026-04-25

  This study demonstrates that ORM2, an acute-phase protein, alleviates pancreatic fibrosis in chronic pancreatitis by inhibiting autophagy in pancreatic stellate cells through binding to ZG16. By dissecting the mechanisms underlying PSC activation, the research identifies ORM2 as a promising therapeutic target for fibrosis modulation and highlights the importance of autophagy regulation in pancreatic function research.

• ω-Agatoxin IVA TFA: Reliable P/Q-Type Channel Block for Neur

  2026-04-24

  This scenario-driven guide addresses real-world challenges in cell viability and synaptic transmission research, highlighting how ω-Agatoxin IVA TFA (SKU C8722) delivers reproducibility, specificity, and validated neuroprotective effects. With data-backed usage guidance and vendor comparison, it empowers biomedical researchers and lab staff to optimize neuronal calcium current recording and epilepsy model workflows.

• Optimizing Cancer and Inflammation Assays with LY2228820

  2026-04-24

  LY2228820, a potent p38 MAP kinase inhibitor, empowers researchers to dissect inflammation and tumor biology with remarkable specificity. This guide delivers practical workflows, troubleshooting strategies, and key insights from frontline studies—helping you harness LY2228820 for advanced anti-inflammatory and cancer research.

• Moxifloxacin in Research: Fluoroquinolone Workflows & Optimi

  2026-04-23

  Leverage Moxifloxacin’s robust DNA gyrase inhibition for reproducible cell-based assays and advanced antibiotic toxicity research. This article guides scientists through protocol setup, workflow enhancements, and troubleshooting strategies, highlighting APExBIO’s Moxifloxacin as an essential tool for probing antiproliferative and metabolic responses in the lab.

• Structural Variants of Cyclosporin: Impact on Mitochondrial

  2026-04-23

  This study systematically compares structural properties and mitochondrial activity of cyclosporin variants B–E, revealing that backbone rigidity critically influences their ability to inhibit the mitochondrial permeability transition pore. Notably, only variants with higher backbone flexibility, similar to Cyclosporin A, effectively block pore opening, advancing mechanistic understanding for immunosuppression and mitochondrial research.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual Fluorescence Benchmark

  2026-04-22

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables quantitative, real-time tracking of mRNA delivery and translation efficiency in living cells. Its Cy5 and EGFP dual reporters, Cap 1 structure, and 5-moUTP modification provide enhanced stability and immune evasion. This product is optimized for advanced gene delivery and functional genomics workflows.

• Anisomycin and JNK Pathway: Precision Tools for Apoptosis Re

  2026-04-22

  Explore how Anisomycin, a potent JNK agonist, enables precision control of apoptosis and cellular stress responses. This article delivers advanced, evidence-based insights and bridges recent mechanistic findings with practical assay optimization.

• Applied Use-Cases of Recombinant Mouse Macrophage Colony Sti

  2026-04-21

  Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag unlocks precise control over macrophage differentiation and function, streamlining workflows in immunology, fibrosis, and oncology research. This guide details stepwise protocols, troubleshooting strategies, and applied insights, leveraging both product validation and novel mechanistic findings.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Precision Tools f

  2026-04-21

  Explore how 10058-F4—a potent c-Myc-Max dimerization inhibitor—redefines targeted transcription factor inhibition and apoptosis assay design. This in-depth article synthesizes new insights from telomerase regulation research and practical workflows for acute myeloid leukemia and prostate cancer models.

• A23187, Free Acid: Precision Calcium Ionophore in Cell Assay

  2026-04-20

  A23187, free acid, from APExBIO, enables robust, tunable elevation of intracellular calcium for dissecting apoptosis, contractility, and signaling pathways. This article delivers evidence-driven protocols, troubleshooting insights, and strategic workflow integration for maximizing reproducibility and discovery impact in cell-based research.

• Targeting Lin28B/Let-7/PBK Axis in TNBC: Ponicidin Mechanism

  2026-04-20

  This study identifies Lin28B as a TNBC-specific therapeutic target and demonstrates that the natural compound ponicidin binds Lin28B, inhibits its oncogenic function, and suppresses tumor growth in vitro and in vivo. These findings provide mechanistic insight for developing targeted therapies in triple-negative breast cancer and highlight the value of advanced immunoblotting platforms in validating low-abundance protein targets.

• Nadolol (SQ-11725) in Hypertension Research: Protocols & Pit

  2026-04-19

  Nadolol (SQ-11725) is a cornerstone for modeling hypertension and angina pectoris in preclinical research, uniquely enabling studies on beta-adrenergic signaling and transporter-mediated pharmacokinetics. This guide translates recent transporter-focused breakthroughs into actionable workflows, troubleshooting, and data-driven assay choices.

• BMS-777607: c-Met Inhibitor for Cancer and Platelet Research

  2026-04-18

  BMS-777607 is redefining selective c-Met inhibition, bridging advanced cancer metastasis models with next-generation hiPSC-derived platelet production. Discover protocol enhancements, troubleshooting strategies, and cited performance metrics that empower translational research and reproducibility.

• I-BET151 (GSK1210151A): Practical Guidance for BET Inhibitio

  2026-04-17

  I-BET151 (GSK1210151A) provides a selective tool for inhibiting BRD2, BRD3, and BRD4 in cancer biology and epigenetic research workflows. It is most appropriate for apoptosis and cell cycle arrest assays in preclinical models, with specific handling and solubility requirements to ensure reproducibility. This compound is not intended for diagnostic or clinical applications.

• CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1

  2026-04-16

  This study demonstrates that Cdc2-like kinase 2 (CLK2) is upregulated in ovarian cancer and confers resistance to platinum chemotherapy by enhancing BRCA1-dependent DNA repair. These findings clarify a key resistance mechanism and identify CLK2 as a potential target for overcoming treatment failure in ovarian cancer.

15325 records 1/1022 page Next 12345 下5页 Last page